Limits...
High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis.

Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, Zhong Q, Wen ZS - Oncotarget (2015)

Bottom Line: IHC results revealed TACC3 expression was significantly correlated to differentiation (p = 0.017) and lymphoid nodal status (p = 0.028).The patients with high-expression of TACC3 had a significantly poor prognosis compared to those of low-expression (p = 0.017), especially in the patients at stages I-II (p = 0.028).Knockdown of TACC3 inhibited the ability of cell proliferation, colony formation and migration.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.

ABSTRACT
To analyze the expression of the transforming acidic coiled-coil protein 3 (TACC3) in esophageal squamous cell carcinoma (ESCC) samples, and to identify whether TACC3 can serve as a biomarker for the diagnosis and prognosis of ESCC, qPCR, western blotting and immunohistochemistry staining (IHC) were utilized to detect the expression of TACC3. Furthermore, cell growth, colony formation, migration ability and the epithelial-mesenchymal transition markers of ESCC cells in which TACC3 were knocked-down were measured. The mRNA and protein levels of TACC3 were higher in ESCC specimens compared to non-tumorous esophageal epithelial tissues. IHC results revealed TACC3 expression was significantly correlated to differentiation (p = 0.017) and lymphoid nodal status (p = 0.028). The patients with high-expression of TACC3 had a significantly poor prognosis compared to those of low-expression (p = 0.017), especially in the patients at stages I-II (p = 0.028). Multivariate analysis indicated that TACC3 expression was an independent prognostic factor for ESCC patients (p = 0.025). Knockdown of TACC3 inhibited the ability of cell proliferation, colony formation and migration. This study first identifies TACC3 not only as a useful biomarker for diagnose and prognosis of ESCC, but also as a potential therapeutic target for patients with ESCC.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier estimates of the probability of survival(A) The five-year overall survival (OS) rate was 50.7% of 209 ESCC patient; (B) High TACC3 expression level was significantly correlated to OS ( p = 0.017) in all ESCC patients. Furthermore, cases were stratified by pathological stage. (C) High TACC3 expression level was significantly associated with OS (p = 0.028) in ESCC patients at Stage II; (D) No significant difference in 5-year OS rate was found between TACC3 high-expression and low-expression in ESCC patients at Stage III.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4466654&req=5

Figure 4: Kaplan–Meier estimates of the probability of survival(A) The five-year overall survival (OS) rate was 50.7% of 209 ESCC patient; (B) High TACC3 expression level was significantly correlated to OS ( p = 0.017) in all ESCC patients. Furthermore, cases were stratified by pathological stage. (C) High TACC3 expression level was significantly associated with OS (p = 0.028) in ESCC patients at Stage II; (D) No significant difference in 5-year OS rate was found between TACC3 high-expression and low-expression in ESCC patients at Stage III.

Mentions: Of the 209 patients in this study, the median follow-up period was 5.2 years (range, 0.3 to 10 years), with 121 cancer-related deaths at the final clinical follow-up. The 5-year overall survival rate was 50.7% for the total study population (Figure 4A). In the Kaplan–Meier analysis, OS was longer for patients with low TACC3 expression than those with high TACC3 expression (p = 0.017, median 6.0 vs. 3.7 years, Figure 4B). Further stratification of patient groups based on stage displayed that the correlation of low TACC3 expression and longer OS was statistically significant in Stage I–II patients with ESCC (p = 0.028, median 7.1 vs. 6.0 years, Figure 4C). However, in Stage III, there was no significant association between low TACC3 expression and longer OS (p = 0.227, median 1.9 vs. 1.6 years, Figure 4D).


High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis.

Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, Zhong Q, Wen ZS - Oncotarget (2015)

Kaplan–Meier estimates of the probability of survival(A) The five-year overall survival (OS) rate was 50.7% of 209 ESCC patient; (B) High TACC3 expression level was significantly correlated to OS ( p = 0.017) in all ESCC patients. Furthermore, cases were stratified by pathological stage. (C) High TACC3 expression level was significantly associated with OS (p = 0.028) in ESCC patients at Stage II; (D) No significant difference in 5-year OS rate was found between TACC3 high-expression and low-expression in ESCC patients at Stage III.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4466654&req=5

Figure 4: Kaplan–Meier estimates of the probability of survival(A) The five-year overall survival (OS) rate was 50.7% of 209 ESCC patient; (B) High TACC3 expression level was significantly correlated to OS ( p = 0.017) in all ESCC patients. Furthermore, cases were stratified by pathological stage. (C) High TACC3 expression level was significantly associated with OS (p = 0.028) in ESCC patients at Stage II; (D) No significant difference in 5-year OS rate was found between TACC3 high-expression and low-expression in ESCC patients at Stage III.
Mentions: Of the 209 patients in this study, the median follow-up period was 5.2 years (range, 0.3 to 10 years), with 121 cancer-related deaths at the final clinical follow-up. The 5-year overall survival rate was 50.7% for the total study population (Figure 4A). In the Kaplan–Meier analysis, OS was longer for patients with low TACC3 expression than those with high TACC3 expression (p = 0.017, median 6.0 vs. 3.7 years, Figure 4B). Further stratification of patient groups based on stage displayed that the correlation of low TACC3 expression and longer OS was statistically significant in Stage I–II patients with ESCC (p = 0.028, median 7.1 vs. 6.0 years, Figure 4C). However, in Stage III, there was no significant association between low TACC3 expression and longer OS (p = 0.227, median 1.9 vs. 1.6 years, Figure 4D).

Bottom Line: IHC results revealed TACC3 expression was significantly correlated to differentiation (p = 0.017) and lymphoid nodal status (p = 0.028).The patients with high-expression of TACC3 had a significantly poor prognosis compared to those of low-expression (p = 0.017), especially in the patients at stages I-II (p = 0.028).Knockdown of TACC3 inhibited the ability of cell proliferation, colony formation and migration.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.

ABSTRACT
To analyze the expression of the transforming acidic coiled-coil protein 3 (TACC3) in esophageal squamous cell carcinoma (ESCC) samples, and to identify whether TACC3 can serve as a biomarker for the diagnosis and prognosis of ESCC, qPCR, western blotting and immunohistochemistry staining (IHC) were utilized to detect the expression of TACC3. Furthermore, cell growth, colony formation, migration ability and the epithelial-mesenchymal transition markers of ESCC cells in which TACC3 were knocked-down were measured. The mRNA and protein levels of TACC3 were higher in ESCC specimens compared to non-tumorous esophageal epithelial tissues. IHC results revealed TACC3 expression was significantly correlated to differentiation (p = 0.017) and lymphoid nodal status (p = 0.028). The patients with high-expression of TACC3 had a significantly poor prognosis compared to those of low-expression (p = 0.017), especially in the patients at stages I-II (p = 0.028). Multivariate analysis indicated that TACC3 expression was an independent prognostic factor for ESCC patients (p = 0.025). Knockdown of TACC3 inhibited the ability of cell proliferation, colony formation and migration. This study first identifies TACC3 not only as a useful biomarker for diagnose and prognosis of ESCC, but also as a potential therapeutic target for patients with ESCC.

Show MeSH
Related in: MedlinePlus